Please login to the form below

Not currently logged in
Email:
Password:

Takeda acquires Nycomed

Takeda Pharmaceutical Company has completed a €9.6bn takeover of Nycomed

Takeda Pharmaceutical Company has acquired Nycomed for €9.6bn on a cash-free, debt-free basis.

The boards of directors of each company unanimously approved the transaction that is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed's US dermatology business.

Takeda said: "This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011–2013 mid-range plan. Takeda has its strong presence in the Japanese and US markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialisation capability."

The acquisition includes the roflumilast franchise, a first-in-class treatment for chronic obstructive pulmonary disease, which is expected to be a major source of revenue growth for Takeda.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics